JPWO2022240688A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022240688A5 JPWO2022240688A5 JP2023568726A JP2023568726A JPWO2022240688A5 JP WO2022240688 A5 JPWO2022240688 A5 JP WO2022240688A5 JP 2023568726 A JP2023568726 A JP 2023568726A JP 2023568726 A JP2023568726 A JP 2023568726A JP WO2022240688 A5 JPWO2022240688 A5 JP WO2022240688A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- composition
- dll3
- agent
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 44
- 229940127276 delta-like ligand 3 Drugs 0.000 claims description 44
- 229960002621 pembrolizumab Drugs 0.000 claims description 16
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229960003301 nivolumab Drugs 0.000 claims description 12
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 239000003246 corticosteroid Substances 0.000 claims description 8
- 238000011518 platinum-based chemotherapy Methods 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 229960003989 tocilizumab Drugs 0.000 claims description 4
- 229940121420 cemiplimab Drugs 0.000 claims 3
- 229940121497 sintilimab Drugs 0.000 claims 3
- 229950007123 tislelizumab Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 description 19
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163186569P | 2021-05-10 | 2021-05-10 | |
| US63/186,569 | 2021-05-10 | ||
| PCT/US2022/028135 WO2022240688A1 (en) | 2021-05-10 | 2022-05-06 | Dosing regimen for combination therapy targeting dll3 and pd-1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024518947A JP2024518947A (ja) | 2024-05-08 |
| JPWO2022240688A5 true JPWO2022240688A5 (https=) | 2025-05-21 |
| JP2024518947A5 JP2024518947A5 (https=) | 2025-05-21 |
Family
ID=84029376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568726A Pending JP2024518947A (ja) | 2021-05-10 | 2022-05-06 | Ｄｌｌ３及びｐｄ－１を標的とする組み合わせ療法のための投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240317856A1 (https=) |
| EP (1) | EP4337252A4 (https=) |
| JP (1) | JP2024518947A (https=) |
| KR (1) | KR20240006585A (https=) |
| CN (1) | CN117377488A (https=) |
| AU (1) | AU2022273509A1 (https=) |
| CA (1) | CA3217141A1 (https=) |
| CL (1) | CL2023003357A1 (https=) |
| IL (1) | IL307646A (https=) |
| MX (1) | MX2023013227A (https=) |
| TW (1) | TW202309092A (https=) |
| WO (1) | WO2022240688A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| JP2025508786A (ja) * | 2022-02-23 | 2025-04-10 | アムジェン インコーポレイテッド | Ｄｌｌ３を標的とする癌治療 |
| EP4630458A2 (en) * | 2022-12-08 | 2025-10-15 | Amgen Inc. | Methods for treating dll3-expressing cancer |
| TW202509075A (zh) * | 2023-05-19 | 2025-03-01 | 德商百靈佳殷格翰國際股份有限公司 | T細胞銜接蛋白治療癌症之用途 |
| CN120168667B (zh) * | 2025-03-18 | 2026-04-14 | 中国科学院近代物理研究所 | 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究（慕尼黑）公司 | Ｄｌｌ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| CN108136015A (zh) * | 2015-08-20 | 2018-06-08 | 艾伯维施特姆森特克斯有限责任公司 | 抗dll3抗体药物缀合物以及使用方法 |
| CA3095920A1 (en) * | 2018-04-10 | 2019-10-17 | Amgen Inc. | Chimeric receptors to dll3 and methods of use thereof |
| TWI848953B (zh) * | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
-
2022
- 2022-05-06 US US18/289,317 patent/US20240317856A1/en active Pending
- 2022-05-06 CN CN202280031401.6A patent/CN117377488A/zh active Pending
- 2022-05-06 CA CA3217141A patent/CA3217141A1/en active Pending
- 2022-05-06 KR KR1020237041314A patent/KR20240006585A/ko active Pending
- 2022-05-06 IL IL307646A patent/IL307646A/en unknown
- 2022-05-06 JP JP2023568726A patent/JP2024518947A/ja active Pending
- 2022-05-06 MX MX2023013227A patent/MX2023013227A/es unknown
- 2022-05-06 AU AU2022273509A patent/AU2022273509A1/en active Pending
- 2022-05-06 EP EP22808092.5A patent/EP4337252A4/en active Pending
- 2022-05-06 WO PCT/US2022/028135 patent/WO2022240688A1/en not_active Ceased
- 2022-05-10 TW TW111117458A patent/TW202309092A/zh unknown
-
2023
- 2023-11-10 CL CL2023003357A patent/CL2023003357A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104271135B (zh) | 在要求减少施用容量的患者中治疗苯达莫司汀响应性状况的方法 | |
| JP2021514354A5 (https=) | ||
| JPWO2022240688A5 (https=) | ||
| JPWO2020250915A5 (https=) | ||
| Loricera et al. | Biologic therapy in ANCA-negative vasculitis | |
| Steuber et al. | Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. | |
| CN101896190A (zh) | 用α胸腺肽和抗细胞毒性T淋巴细胞相关抗原4(CTLA4)的抗体的组合治疗黑素瘤 | |
| JP2022501332A5 (https=) | ||
| JPWO2020191326A5 (https=) | ||
| TW202535468A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| JP2021152002A5 (https=) | ||
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| Engelsman et al. | Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an EORTC study. | |
| JPWO2021092134A5 (https=) | ||
| JPWO2023164474A5 (https=) | ||
| WO2024183817A1 (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| JPWO2022053990A5 (https=) | ||
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| JPWO2023099622A5 (https=) | ||
| US20250019441A1 (en) | Treatment of cancer with anti-ilt2 antibodies | |
| Yu et al. | Gilteritinib as a bridge to allogeneic hematopoietic stem cell transplantation in adult patients with refractory/relapsed acute myeloid leukemia with FLT3 mutations | |
| JP2025126668A (ja) | 人免疫グロブリンｇを有効成分として含有する、腎臓移植後の抗体関連型拒絶反応の治療剤 | |
| JPWO2022047083A5 (https=) | ||
| JPWO2020012244A5 (https=) | ||
| WO2025160930A1 (zh) | 母帕司汀(Muparfostat)治疗胰腺癌的用途 |